APA (7th ed.) Citation

MR, S., MR, S., MD, M., NW, C., DP, D., JS, d. B., . . . ND, J. (2018). Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of oncology : official journal of the European Society for Medical Oncology, 29(5), 1235. https://doi.org/10.1093/annonc/mdy072

Chicago Style (17th ed.) Citation

MR, Sydes, et al. "Adding Abiraterone or Docetaxel to Long-term Hormone Therapy for Prostate Cancer: Directly Randomised Data from the STAMPEDE Multi-arm, Multi-stage Platform Protocol." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 5 (2018): 1235. https://doi.org/10.1093/annonc/mdy072.

MLA (9th ed.) Citation

MR, Sydes, et al. "Adding Abiraterone or Docetaxel to Long-term Hormone Therapy for Prostate Cancer: Directly Randomised Data from the STAMPEDE Multi-arm, Multi-stage Platform Protocol." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, no. 5, 2018, p. 1235, https://doi.org/10.1093/annonc/mdy072.